Habitual Protein Intake and Muscle Protein Synthesis
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Nov 12, 2013
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
During the adult life skeletal muscle mass remains fairly constant until the fourth or fifth decade. Then, the slow process of sarcopenia (the age-related loss of muscle mass) is believed to begin. The maintenance of skeletal muscle mass is regulated by a balance between the opposing processes of muscle protein synthesis and muscle protein breakdown. Food intake, dietary protein in particular, stimulates muscle protein synthesis and allows net muscle protein accretion throughout the day, which allows the normal maintenance of muscle mass in healthy individuals. Many studies have described t...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy males
- • Age between 55 and 75 y
- • BMI between 18.5 and 30 kg/m2
- Exclusion Criteria:
- • Lactose intolerance
- • Smoking and alcohol abuse
- • Diabetes
- • Diagnosed GI tract diseases
- • Arthritic conditions
- • A history of neuromuscular problems
- • Any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
- • Use of anticoagulants
- • Participation in exercise program
- • Hypertension, high blood pressure that is above 140/90 mmHg.
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, Limburg, Netherlands
Patients applied
Trial Officials
Luc JC van Loon, PhD
Principal Investigator
Maastricht University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials